ANAB – AnaptysBio Inc
ANAB
$48.38Name : AnaptysBio, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,446,331,904.00
EPSttm : -0.96
AnaptysBio, Inc.
$48.38
ANAB — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
19.31
Margin Of Safety %
Put/Call OI Ratio
1.12
EPS Next Q Diff
1.17
EPS Last/This Y
EPS This/Next Y
0.34
Price
48.42
Target Price
79.71
Analyst Recom
1.14
Performance Q
-15.09
Upside
73.3%
Beta
0.86
Ticker: ANAB
22 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-12 | ANAB | 46 | 0.49 | 0.09 | 3532 |
| 2026-10-13 | ANAB | 45.59 | 0.48 | 2.95 | 3556 |
| 2026-10-14 | ANAB | 46.54 | 0.50 | 5.50 | 3602 |
| 2026-10-15 | ANAB | 48.68 | 0.50 | 17.00 | 3604 |
| 2026-10-16 | ANAB | 46.68 | 0.50 | 999.99 | 3608 |
| 2026-10-19 | ANAB | 49.28 | 0.51 | 0.53 | 3413 |
| 2026-10-20 | ANAB | 45.28 | 0.51 | 2.45 | 3489 |
| 2026-10-21 | ANAB | 47.92 | 0.53 | 0.44 | 3560 |
| 2026-10-22 | ANAB | 48.11 | 1.00 | 999.99 | 3167 |
| 2026-10-23 | ANAB | 48.7 | 1.01 | 7.73 | 3177 |
| 2026-10-26 | ANAB | 48.74 | 1.04 | 0.50 | 3225 |
| 2026-10-27 | ANAB | 49.74 | 1.04 | 0.06 | 3227 |
| 2026-10-28 | ANAB | 50.46 | 1.04 | 2.54 | 3223 |
| 2026-10-29 | ANAB | 48.65 | 1.08 | 1.30 | 3402 |
| 2026-10-30 | ANAB | 48.29 | 1.07 | 999.99 | 3429 |
| 2026-11-02 | ANAB | 47.08 | 1.10 | 11.50 | 3470 |
| 2026-11-03 | ANAB | 47.78 | 1.13 | 0.40 | 3512 |
| 2026-11-04 | ANAB | 47.6 | 1.12 | 1.75 | 3515 |
| 2026-11-05 | ANAB | 45.58 | 1.11 | 6.00 | 3515 |
| 2026-11-06 | ANAB | 46.46 | 1.11 | 0.25 | 3511 |
| 2026-11-09 | ANAB | 47.98 | 1.11 | 5.13 | 3516 |
| 2026-11-10 | ANAB | 48.42 | 1.12 | 7.00 | 3539 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
22 items
«
‹
Current Page1 of 1
›
»
22 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-12 | ANAB | 46.03 | 53.1 | -64.8 | 4.35 |
| 2026-10-13 | ANAB | 45.67 | 53.1 | -66.7 | 4.35 |
| 2026-10-14 | ANAB | 46.58 | 53.1 | -61.3 | 4.35 |
| 2026-10-15 | ANAB | 48.66 | 53.1 | -53.3 | 4.35 |
| 2026-10-16 | ANAB | 46.58 | 53.1 | -72.6 | 4.35 |
| 2026-10-19 | ANAB | 49.26 | 53.1 | -55.4 | 4.35 |
| 2026-10-20 | ANAB | 49.26 | 53.1 | -55.4 | 4.35 |
| 2026-10-21 | ANAB | 45.43 | 53.1 | -69.5 | 4.35 |
| 2026-10-22 | ANAB | 48.11 | 53.1 | -64.4 | 4.35 |
| 2026-10-23 | ANAB | 48.77 | 53.1 | -64.4 | 4.35 |
| 2026-10-26 | ANAB | 48.76 | 53.1 | -64.9 | 4.35 |
| 2026-10-27 | ANAB | 49.66 | 53.1 | -61.7 | 4.20 |
| 2026-10-28 | ANAB | 50.46 | 53.1 | -59.1 | 4.20 |
| 2026-10-29 | ANAB | 48.62 | 53.1 | -71.5 | 4.20 |
| 2026-10-30 | ANAB | 48.30 | 2.1 | -66.2 | 4.20 |
| 2026-11-02 | ANAB | 47.04 | 2.1 | -69.5 | 4.20 |
| 2026-11-03 | ANAB | 47.81 | 2.1 | -66.8 | 4.20 |
| 2026-11-04 | ANAB | 47.56 | 2.1 | -65.7 | 4.20 |
| 2026-11-05 | ANAB | 45.58 | 2.1 | -72.2 | 4.20 |
| 2026-11-06 | ANAB | 46.47 | 2.1 | -61.5 | 4.20 |
| 2026-11-09 | ANAB | 47.93 | 2.1 | -59.7 | 4.20 |
| 2026-11-10 | ANAB | 48.42 | 2.1 | -63.4 | 4.20 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
22 items
«
‹
Current Page1 of 1
›
»
21 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-12 | ANAB | -0.25 | 5.57 | 18.77 |
| 2026-10-13 | ANAB | -0.25 | 5.57 | 18.77 |
| 2026-10-14 | ANAB | -0.25 | 5.57 | 18.77 |
| 2026-10-15 | ANAB | -0.25 | 5.57 | 18.77 |
| 2026-10-16 | ANAB | -0.25 | 5.57 | 18.75 |
| 2026-10-19 | ANAB | -0.25 | 5.61 | 18.75 |
| 2026-10-20 | ANAB | -0.25 | 5.61 | 18.75 |
| 2026-10-21 | ANAB | -0.25 | 5.61 | 18.75 |
| 2026-10-22 | ANAB | -0.25 | 5.61 | 18.75 |
| 2026-10-23 | ANAB | -0.25 | 5.61 | 18.75 |
| 2026-10-26 | ANAB | -0.25 | 4.79 | 18.75 |
| 2026-10-27 | ANAB | -0.25 | 4.79 | 19.31 |
| 2026-10-28 | ANAB | -0.25 | 4.79 | 19.31 |
| 2026-10-29 | ANAB | -0.25 | 4.79 | 19.31 |
| 2026-10-30 | ANAB | -0.25 | 4.79 | 19.31 |
| 2026-11-02 | ANAB | -0.25 | 5.15 | 19.31 |
| 2026-11-03 | ANAB | -0.25 | 5.15 | 19.31 |
| 2026-11-05 | ANAB | -0.25 | 5.15 | 19.31 |
| 2026-11-06 | ANAB | -0.25 | 5.15 | 19.31 |
| 2026-11-09 | ANAB | -0.25 | 4.15 | 19.31 |
| 2026-11-10 | ANAB | -0.25 | 4.15 | 19.31 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
21 items
«
‹
Current Page1 of 1
›
»
Last Quarter Act. EPS
-0.11
Avg. EPS Est. Current Quarter
0.53
Avg. EPS Est. Next Quarter
1.06
Insider Transactions
-0.25
Institutional Transactions
4.15
Beta
0.86
Average Sales Estimate Current Quarter
33
Average Sales Estimate Next Quarter
52
Fair Value
Quality Score
67
Growth Score
86
Sentiment Score
70
Actual DrawDown %
33.1
Max Drawdown 5-Year %
-69.3
Target Price
79.71
P/E
7.51
Forward P/E
PEG
P/S
6.09
P/B
135.88
P/Free Cash Flow
80.04
EPS
6.45
Average EPS Est. Cur. Y
4.2
EPS Next Y. (Est.)
4.54
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
82.37
Relative Volume
0.51
Return on Equity vs Sector %
-100
Return on Equity vs Industry %
-100
EPS 1 7Days Diff
-0.2
EPS 1 30Days Diff
-0.58
EBIT Estimation
-63.4
◆
ANAB
Healthcare
$48.38
📉
N/A
Swing / Pullback
Buy the dip on strong trends
WEAK
Trend
2/20
Pullback
13/25
Volume
11/15
Valuation
12/20
TP/AR
2/10
Options
0/10
RSI
49.8
Range 1M
52%
Sup Dist
4%
🚀
N/A
Momentum Growth
Ride accelerating trends
WEAK
Momentum
1/25
Growth
14/30
Estimates
6/20
Inst/Vol
5/15
Options
0/10
EPS Yr
0%
EPS NY
0%
52W%
52.3%
💎
N/A
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+34.2% upside
Quality
13/30
Valuation
10/30
Growth
9/25
Stability
6/10
LT Trend
0/5
Upside
+34.2%
Quality
67
Click a card to see score breakdown
Full Analysis →
ANAB — P/E HistoricalBiotechnology
Sector: Healthcare
Industry: Biotechnology
Employees:
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
ANAB
Latest News
—
Caricamento notizie per ANAB…
stock quote shares ANAB – AnaptysBio Inc Stock Price stock today
news today ANAB – AnaptysBio Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ANAB – AnaptysBio Inc yahoo finance google finance
stock history ANAB – AnaptysBio Inc invest stock market
stock prices ANAB premarket after hours
ticker ANAB fair value insiders trading